Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT. - Kharfan-Dabaja, M A; Labopin, M; Bazarbachi, A; Hamladji, R M; Blaise, D; Socié, G; Lioure, B; Bermudez, A; Lopez-Corral, L; Or, R; Arcese, W; Fegueux, N; et al. (Bone Marrow Transplantation, 2014)